CA2478401A1 - Treatment of surfaces populated by bacteria - Google Patents
Treatment of surfaces populated by bacteria Download PDFInfo
- Publication number
- CA2478401A1 CA2478401A1 CA002478401A CA2478401A CA2478401A1 CA 2478401 A1 CA2478401 A1 CA 2478401A1 CA 002478401 A CA002478401 A CA 002478401A CA 2478401 A CA2478401 A CA 2478401A CA 2478401 A1 CA2478401 A1 CA 2478401A1
- Authority
- CA
- Canada
- Prior art keywords
- secretions
- composition
- lucilia sericata
- excretions
- biofilm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 26
- 241000736227 Lucilia sericata Species 0.000 claims abstract description 37
- 230000028327 secretion Effects 0.000 claims abstract description 36
- 230000000694 effects Effects 0.000 claims abstract description 29
- 230000003115 biocidal effect Effects 0.000 claims abstract description 16
- 239000004098 Tetracycline Substances 0.000 claims abstract description 11
- 230000029142 excretion Effects 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 11
- 229960002180 tetracycline Drugs 0.000 claims abstract description 11
- 229930101283 tetracycline Natural products 0.000 claims abstract description 11
- 235000019364 tetracycline Nutrition 0.000 claims abstract description 11
- 150000003522 tetracyclines Chemical class 0.000 claims abstract description 11
- 239000008380 degradant Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 14
- 230000000845 anti-microbial effect Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 230000015556 catabolic process Effects 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 238000006731 degradation reaction Methods 0.000 claims description 9
- 210000000087 hemolymph Anatomy 0.000 claims description 9
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 6
- 239000004599 antimicrobial Substances 0.000 claims description 5
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 4
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 4
- 108010022999 Serine Proteases Proteins 0.000 claims description 4
- 102000012479 Serine Proteases Human genes 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 1
- 230000001418 larval effect Effects 0.000 abstract description 9
- 239000003242 anti bacterial agent Substances 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 241000257166 Lucilia cuprina Species 0.000 abstract description 2
- VFFNZZXXTGXBOG-LURJTMIESA-N (+)-a(S)-butyr-amido-r-butyrolactone Chemical compound CCCC(=O)N[C@H]1CCOC1=O VFFNZZXXTGXBOG-LURJTMIESA-N 0.000 description 17
- VFFNZZXXTGXBOG-UHFFFAOYSA-N N-butanoyl-L-homoserine lactone Natural products CCCC(=O)NC1CCOC1=O VFFNZZXXTGXBOG-UHFFFAOYSA-N 0.000 description 17
- 206010052428 Wound Diseases 0.000 description 17
- 208000027418 Wounds and injury Diseases 0.000 description 17
- 230000001580 bacterial effect Effects 0.000 description 13
- 230000012010 growth Effects 0.000 description 12
- 230000032770 biofilm formation Effects 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- PHSRRHGYXQCRPU-AWEZNQCLSA-N N-(3-oxododecanoyl)-L-homoserine lactone Chemical compound CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O PHSRRHGYXQCRPU-AWEZNQCLSA-N 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000018612 quorum sensing Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000894243 Sericata Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PMHUSCHKTSTQEP-UHFFFAOYSA-N (4-carbamimidoylphenyl)methanesulfonyl fluoride Chemical compound NC(=N)C1=CC=C(CS(F)(=O)=O)C=C1 PMHUSCHKTSTQEP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000234671 Ananas Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 241000257161 Calliphoridae Species 0.000 description 1
- 108050004290 Cecropin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108700022013 Insecta cecropin B Proteins 0.000 description 1
- 241000920471 Lucilia caesar Species 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 102100032800 Spermine oxidase Human genes 0.000 description 1
- 101000693619 Starmerella bombicola Lactone esterase Proteins 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 238000009428 plumbing Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 102000005428 serine esterase Human genes 0.000 description 1
- 108020002447 serine esterase Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960004533 streptodornase Drugs 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/10—Animals; Substances produced thereby or obtained therefrom
- A01N63/14—Insects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
- A01N61/02—Mineral oils; Tar oils; Tar; Distillates, extracts or conversion products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Insects & Arthropods (AREA)
- Plant Pathology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Animal Husbandry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0205593.7 | 2002-03-09 | ||
| GBGB0205593.7A GB0205593D0 (en) | 2002-03-09 | 2002-03-09 | Treatment of surfaces populated by bacteria |
| PCT/GB2003/000959 WO2003075654A2 (en) | 2002-03-09 | 2003-03-06 | Treatment of surfaces populated by bacteria with a lucilia sericata extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2478401A1 true CA2478401A1 (en) | 2003-09-18 |
Family
ID=9932659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002478401A Abandoned CA2478401A1 (en) | 2002-03-09 | 2003-03-06 | Treatment of surfaces populated by bacteria |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050260183A1 (https=) |
| EP (1) | EP1485112A2 (https=) |
| JP (1) | JP2005525849A (https=) |
| CN (1) | CN100496514C (https=) |
| CA (1) | CA2478401A1 (https=) |
| GB (2) | GB0205593D0 (https=) |
| WO (1) | WO2003075654A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2422664A (en) * | 2005-01-28 | 2006-08-02 | Ethicon Inc | Device for detecting an enzyme in a sample |
| GB0607495D0 (en) * | 2006-04-13 | 2006-05-24 | Secr Defence | Larval enzymes |
| GB0700946D0 (en) * | 2007-01-18 | 2007-02-28 | Uws Ventures Ltd | Antimicrobial composition and a method of controlling contamination and infection using said composition |
| EP1994930A1 (en) * | 2007-05-22 | 2008-11-26 | Novartis AG | Triazol compounds for treating biofilm formation |
| ES2342807B2 (es) * | 2008-08-01 | 2011-03-18 | Universidade De Santiago De Compostela | Uso de bacterias del genero tenacibaculum para quorum quenching. |
| US8486032B2 (en) * | 2008-12-24 | 2013-07-16 | Kci Licensing, Inc. | Reduced-pressure treatment systems and methods employing debridement mechanisms |
| GB2474251A (en) * | 2009-10-08 | 2011-04-13 | Uws Ventures Ltd | Antimicrobial composition and method of controlling contamination or infections using said composition |
| GB201121768D0 (en) | 2011-12-16 | 2012-02-01 | Univ Swansea | Compounds |
| FR3026746B1 (fr) | 2014-10-03 | 2021-09-10 | Pierre Furtos | Procede de production d'antibiotiques cibles a partir d'insectes |
| EP3120866A1 (en) * | 2015-07-24 | 2017-01-25 | Zymetech ehf. | Use of marine serine proteases for removal, prevention and inhibition of formation and growth of biofilms |
| JP7007539B2 (ja) * | 2018-03-23 | 2022-02-10 | 栗田工業株式会社 | Ｎ－アシル化ホモセリンラクトン（ａｈｌ）ラクトナーゼ、それを用いた水処理剤及び水処理方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09132532A (ja) * | 1995-09-06 | 1997-05-20 | Mitsui Norin Kk | 抗生物質の抗菌力増強方法 |
| DE19901134C2 (de) * | 1999-01-14 | 2002-11-21 | Wilhelm Fleischmann | Verbandsmaterial |
| GB9925005D0 (en) * | 1999-10-22 | 1999-12-22 | Univ Nottingham | The treatment of wounds |
| CA2456814A1 (en) * | 2001-08-10 | 2003-02-20 | Aventis Pharma Deutschland Gmbh | Use of fly larvae extracts for the treatment of wounds |
-
2002
- 2002-03-09 GB GBGB0205593.7A patent/GB0205593D0/en not_active Ceased
-
2003
- 2003-03-06 EP EP03712317A patent/EP1485112A2/en not_active Withdrawn
- 2003-03-06 WO PCT/GB2003/000959 patent/WO2003075654A2/en not_active Ceased
- 2003-03-06 CA CA002478401A patent/CA2478401A1/en not_active Abandoned
- 2003-03-06 JP JP2003573941A patent/JP2005525849A/ja active Pending
- 2003-03-06 US US10/506,948 patent/US20050260183A1/en not_active Abandoned
- 2003-03-06 CN CNB038099446A patent/CN100496514C/zh not_active Expired - Fee Related
- 2003-03-06 GB GB0419331A patent/GB2401788B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003075654A2 (en) | 2003-09-18 |
| GB2401788A (en) | 2004-11-24 |
| US20050260183A1 (en) | 2005-11-24 |
| JP2005525849A (ja) | 2005-09-02 |
| EP1485112A2 (en) | 2004-12-15 |
| GB2401788B (en) | 2006-10-18 |
| GB0419331D0 (en) | 2004-09-29 |
| CN1649606A (zh) | 2005-08-03 |
| AU2003216995A1 (en) | 2003-09-22 |
| CN100496514C (zh) | 2009-06-10 |
| WO2003075654A3 (en) | 2004-03-25 |
| AU2003216995B2 (en) | 2006-11-02 |
| GB0205593D0 (en) | 2002-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jaklič et al. | Selective antimicrobial activity of maggots against pathogenic bacteria | |
| Wollina et al. | Biosurgery in wound healing–the renaissance of maggot therapy | |
| Wu et al. | Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces | |
| Nagoba et al. | Acetic acid treatment of pseudomonal wound infections–a review | |
| Mullai et al. | Bactericidal activity of different types of honey against clinical and environmental isolates of Pseudomonas aeruginosa | |
| Nigam et al. | Maggot therapy: the science and implication for CAM Part I—history and bacterial resistance | |
| Cazander et al. | The influence of maggot excretions on PAO1 biofilm formation on different biomaterials | |
| US20050260183A1 (en) | Treatment of surfaces populated by bacteria with a lucilia sericata extract | |
| WO2007100917A2 (en) | Antimicrobials and related methods | |
| Abedon | Bacteriophage-mediated biocontrol of wound infections, and ecological exploitation of biofilms by phages | |
| Mencucci et al. | Antimicrobial activity of antibiotic-treated amniotic membrane: An in vitro study | |
| Dakhil et al. | Adjunctive therapies for bacterial keratitis | |
| Valachova et al. | Lucilia sericata medicinal maggots: a new source of antimicrobial compounds | |
| Limsopatham et al. | Sterilization of blow fly eggs, Chrysomya megacephala and Lucilia cuprina,(Diptera: Calliphoridae) for maggot debridement therapy application | |
| Nigam et al. | The antimicrobial activity of medicinal Maggots | |
| Cooper et al. | Biofilms, wound infection and the issue of control | |
| EP0555116B1 (fr) | Compositions à base d'antiseptiques et leurs applications | |
| AU2003216995B9 (en) | Treatment of surfaces populated by bacteria with a lucilia sericata extract | |
| Tambekar et al. | Prevalence and antimicrobial susceptibility pattern of methicillin resistant Staphylococcus aureus from healthcare and community associated sources | |
| Thomas et al. | The use of fly larvae in the treatment of wounds | |
| KR102716814B1 (ko) | 과수 화상병에 특이적인 신규 박테리오파지 및 이의 이용 | |
| Yau et al. | Antibacterial effect of donor corneas stored in gentamicin-enriched McCarey-Kaufman medium | |
| Cooper et al. | The role of antimicrobial agents in wound care | |
| ALBEE | The treatment of osteomyelitis by bacteriophage | |
| US20240148932A1 (en) | Wound dressing with preventive biofilm additive |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |